Agency Officials, Experts Offer Advice On Product Recalls
This article was originally published in The Silver Sheet
Executive Summary
RECALLS WON'T BE AS DIFFICULT if manufacturers handle them properly, FDA says. “Successfully handling recalls is one of the key activities that a firm is going to have to do,” says Kimber Richter, a CDRH medical officer. FDA offers advice on recall notifications and risk evaluations
You may also be interested in...
Top Reasons Why Products Are Recalled
FDA REVEALS THE MOST COMMON ROOT CAUSES for medical device recalls. No. 1: components that do not conform to specifications.
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.